NeuroblastomaPsyRareCareNCT05245123
Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families
An observational study of Neuroblastoma and Nephroblastoma, run by Universitätsklinikum Hamburg-Eppendorf at 2 sites in Germany.
Trial summary
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings. Read more about this study
- Who is it for?
- Ages 1 month to 17 years
- Conditions the study is for
- Neuroblastoma, Nephroblastoma, Hepatoblastoma
- How many people
- 100 participants
- Where
- 2 sitesGermany
- Study dates
- 21 Feb 2022to 31 Mar 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 17 years
- All sexes
- Child
Study population: Clinical study participants for the diagnostic study are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Center Mannheim due to a rare pediatric disease. Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure at the University Medical Center Hamburg-Eppendorfin and University Medical Center Mannheim the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
Who may be able to join
- Family with at least one child between 0 and 17 years with rare solid abdominal tumors.
- Consent to participate in the study.
- Sufficient knowledge of the German language of parents and children.
- Family with at least one child between 0 and 17 years who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints
- Consent to participate in the study.
- Sufficient knowledge of the German language of parents and children.
Who cannot join
- Severe acute physical, mental and/or cognitive impairment of the child, so that the questionnaire survey does not appear possible and/or unreasonable at this stage.
- Families of children with a congenital or chronic disease.
Trial locations and contacts
2 sites in 1 country.
Germany2 sites
University Medical Center Hamburg-Eppendorf
Hamburg, 20251
University Medical Center Mannheim
Mannheim, Baden-Wurttemberg, 68167
About this study
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings. The aim of the present research project is to examine the psychosocial burden of the children with rare solid abdominal tumors and their family in order to draw attention to a possible psychosocial care gap in this population.
Read the detailed description
The central objective of the cross-sectional study is to show the psychosocial supply gap for families with children and adolescents affected by rare diseases in the field of oncology pediatric surgery. Among the rare diseases that are included are rare solid abdominal tumors. In order to have a comparative sample, additional data of a matched control group are collected. Central standardized psychosocial outcomes will be assessed from the perspectives of the parents and the affected child.
- Conditions
- Neuroblastoma, Nephroblastoma, Hepatoblastoma
- Keywords
- rare diseases
- Medical subject headings
- Neuroblastoma, Wilms Tumor, Hepatoblastoma, Rare Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Families of rare diseased children | Clinical study participants are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Centre Mannheim due to the rare disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments. | |
| Families in the comparative control group | Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Life of the parents (EQ-5D)
Quality of Life (QoL) of the parents, assessed from the perspective of the parents by the instrument "European Quality of Life Five Dimension" (EQ-5D; Hinz et al., 2006). The instrument consists of 5 dimensions, which are answered on a three-point scale. Higher scores indicate greater QoL.
Measured: 1 minutes
Health-related Quality of Life of the parents (SF-12)
Health-related Quality of Life (HRQoL) of the parents, assessed from the perspective of the parents by the "Short-Form-12" (SF-12; Morfeld, Kirchberger \& Bullinger, 2011). The instrument consists of 12 items. Higher scores indicate greater HRQoL.
Measured: 4 minutes
Severity of depression (PHQ-9)
Severity of depression, will be assessed with the 9-question Patient Health Questionnaire (PHQ-9; Löwe et al., 2015). The instrument consists of 9 items. Higher scores indicate greater depression levels.
Measured: 2 minutes
Severity of generalized anxiety disorder
Generalizied Anxiety Disorder Scale-7 (GAD-7; Spitzer, Kroenke \& Löwe, 2006). The instrument consists of 7 items. Higher score indicate greater anxiety levels.
Measured: 1 minutes
Mental health of the parents (BSI-18)
Mental health of the parents, assessed from the perspective of the parents by the "Brief Symptom Inventory-18" (BSI-18; Spitzer et al., 2011). The instrument consists of 18 items, which are answered on a five-point Likert scale (0 to 4). Higher BSI scores indicate greater psychological distress.
Measured: 4 minutes
Health-related quality of life of the chronically-ill children/adolescents (Peds-QL 4.0)
Health-related quality of life of the chronically-ill children/adolescents, assessed from the perspective of the child/adolescent (from 10 years of age) and from the perspective of the parents by the "Pediatric Quality of Life Inventory 4.0" (Peds-QL 4.0; (Varni, Seid, \& Kurtin, 2001). Items will be linearly transformed to a scale of 0 to 100, with higher scores indicating better HRQoL.
Measured: 4 minutes
Psychiatric disorders of the chronically-ill children/adolescents (SDQ)
Psychiatric disorders of the chronically-ill children/adolescents assessed perspective of the child/adolescent and from the perspective of the parents by the "Strengths and Difficulties Questionnaire" (SDQ; Klasen, Woerner, Rothenberger, \& Goodman, 2003). Items are rated on a three-point Likert scale (0 to 2). Higher scores represent greater psychopathology or greater prosocial behavior.
Measured: 4 minutes
Secondary outcomes (6)
Social support of the parents, of the chronically-ill children/adolescents (OSSS)
Social support of the parents, of the chronically-ill children/adolescents and of the siblings, assessed from the perspective of the parents, of the chronically-ill children/adolescents and from the sibling, respectively, by the "Oslo Social Support Scale" (OSSS; Dalgard, 2006). The sum score ranges from 3 to 14. The higher the sum score, the stronger the social support
Measured: 3 minutes
Coping of the parents (CHIP-D)
Coping of the parents, assessed from the perspective of the parents by the German version of the "Coping Health Inventory for Parents" (CHIP-D; McCubbin, McCubbin, Cauble \& Goldbeck, 2001). Items are rated on a four-point Likert scale (0 to 3). Higher scores represent greater use of the respective coping pattern.
Measured: 3 minutes
Family relationships, family dynamics and functionality (FB-A)
Family relationships, family dynamics and functionality, assessed from the perspective of the parents, of the chronically-ill children/adolescents and from the sibling, respectively by "Familienbögen" (FB-A; Cierpka \& Frevert, 1994). Items are rated on a four-point Likert scale (0 to 3)
Measured: 3 minutes
Familial predispositions (FaBel)
familial predispositions assessed from the perspective of the parents by the "Familien-Belastungs-Fragebogen" (FaBel; Ravens-Sieberer, 2001). Items are rated on a four-point Likert scale ranging from 1 (is not right at all) to 4 (is completely right).
Measured: 3 minutes
Satisfaction with the relationship and parenting relationship of the parents (PFB)
Satisfaction with the relationship and parenting relationship of the parents, assessed from the perspective of the parents by the "Partnerschaftsfragebogen" (PFB; Hahlweg, 2016).
Measured: 4 minutes
Parent-child communication (PACS)
Parent-child communication was assessed from the perspective of the child/adolescent and from the perspective of the parents by the "Parent-Adolescent Communication Scale" (PACS; Barnes \& Olsen, 1982). Items are rated on a five-point Likert scale.
Measured: 4 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2022
- Study start21 Feb 2022
- Primary completion31 Mar 2023
- Study completion31 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeuroblastomaStudies of the same condition, open and under way.
- More trials run by Universitätsklinikum Hamburg-EppendorfThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Johannes Boettcher, Universitätsklinikum Hamburg-Eppendorf
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05245123
- Sponsor's protocol ID
- 2021-100605-BO-ff
- Acronym
- PsyRareCare
- Status last verified
- Jun 2024
- First submitted
- 28 Jan 2022
- Last updated
- 11 Jun 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families
- ClinicalTrials.gov ID
- NCT05245123
- Acronym / sponsor ID
- PsyRareCare / 2021-100605-BO-ff
- Conditions
- Neuroblastoma, Nephroblastoma, Hepatoblastoma
- Keywords
- rare diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Universitätsklinikum Hamburg-EppendorfUniversity, hospital or other
- Study start
- 21 Feb 2022 (actual)
- Primary completion
- 31 Mar 2023 (actual)
- Study completion
- 31 Mar 2023 (actual)
- First posted
- 17 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings. The aim of the present research project is to examine the psychosocial burden of the children with rare solid abdominal tumors and their family in order to draw attention to a possible psychosocial care gap in this population.
Detailed description
The central objective of the cross-sectional study is to show the psychosocial supply gap for families with children and adolescents affected by rare diseases in the field of oncology pediatric surgery. Among the rare diseases that are included are rare solid abdominal tumors. In order to have a comparative sample, additional data of a matched control group are collected. Central standardized psychosocial outcomes will be assessed from the perspectives of the parents and the affected child.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Families of rare diseased children | – | –Clinical study participants are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Centre Mannheim due to the rare disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments. |
| Families in the comparative control group | – | –Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation. |
Who may qualify
- Ages
- 1 month to 17 years
- Sex
- All
- Age groups
- Child
- Study population
- Clinical study participants for the diagnostic study are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Center Mannheim due to a rare pediatric disease. Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure at the University Medical Center Hamburg-Eppendorfin and University Medical Center Mannheim the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
Key inclusion criteria (6 listed)
- Family with at least one child between 0 and 17 years with rare solid abdominal tumors.
- Consent to participate in the study.
- Sufficient knowledge of the German language of parents and children.
- Family with at least one child between 0 and 17 years who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints
- Consent to participate in the study.
Key exclusion criteria (2 listed)
- Severe acute physical, mental and/or cognitive impairment of the child, so that the questionnaire survey does not appear possible and/or unreasonable at this stage.
- Families of children with a congenital or chronic disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Quality of Life of the parents (EQ-5D)
Time frame: 1 minutes
Quality of Life (QoL) of the parents, assessed from the perspective of the parents by the instrument "European Quality of Life Five Dimension" (EQ-5D; Hinz et al., 2006). The instrument consists of 5 dimensions, which are answered on a three-point scale. Higher scores indicate greater QoL.
Health-related Quality of Life of the parents (SF-12)
Time frame: 4 minutes
Health-related Quality of Life (HRQoL) of the parents, assessed from the perspective of the parents by the "Short-Form-12" (SF-12; Morfeld, Kirchberger \& Bullinger, 2011). The instrument consists of 12 items. Higher scores indicate greater HRQoL.
Severity of depression (PHQ-9)
Time frame: 2 minutes
Severity of depression, will be assessed with the 9-question Patient Health Questionnaire (PHQ-9; Löwe et al., 2015). The instrument consists of 9 items. Higher scores indicate greater depression levels.
Severity of generalized anxiety disorder
Time frame: 1 minutes
Generalizied Anxiety Disorder Scale-7 (GAD-7; Spitzer, Kroenke \& Löwe, 2006). The instrument consists of 7 items. Higher score indicate greater anxiety levels.
Mental health of the parents (BSI-18)
Time frame: 4 minutes
Mental health of the parents, assessed from the perspective of the parents by the "Brief Symptom Inventory-18" (BSI-18; Spitzer et al., 2011). The instrument consists of 18 items, which are answered on a five-point Likert scale (0 to 4). Higher BSI scores indicate greater psychological distress.
Health-related quality of life of the chronically-ill children/adolescents (Peds-QL 4.0)
Time frame: 4 minutes
Health-related quality of life of the chronically-ill children/adolescents, assessed from the perspective of the child/adolescent (from 10 years of age) and from the perspective of the parents by the "Pediatric Quality of Life Inventory 4.0" (Peds-QL 4.0; (Varni, Seid, \& Kurtin, 2001). Items will be linearly transformed to a scale of 0 to 100, with higher scores indicating better HRQoL.
Psychiatric disorders of the chronically-ill children/adolescents (SDQ)
Time frame: 4 minutes
Psychiatric disorders of the chronically-ill children/adolescents assessed perspective of the child/adolescent and from the perspective of the parents by the "Strengths and Difficulties Questionnaire" (SDQ; Klasen, Woerner, Rothenberger, \& Goodman, 2003). Items are rated on a three-point Likert scale (0 to 2). Higher scores represent greater psychopathology or greater prosocial behavior.
6 secondary outcomes
Social support of the parents, of the chronically-ill children/adolescents (OSSS)
Time frame: 3 minutes
Coping of the parents (CHIP-D)
Time frame: 3 minutes
Family relationships, family dynamics and functionality (FB-A)
Time frame: 3 minutes
Familial predispositions (FaBel)
Time frame: 3 minutes
Satisfaction with the relationship and parenting relationship of the parents (PFB)
Time frame: 4 minutes
Parent-child communication (PACS)
Time frame: 4 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Neuroblastoma
RecruitingPhase 1/2
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma
Active, not recruitingObservational study
Genomic Structural Variation in Cancer Susceptibility
Breast Cancer, Colon Cancer
RecruitingPhase 2
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma
RecruitingObservational study
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Endocrine Tumors, Thyroid Neoplasms
RecruitingPhase 1
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuroblastoma and Nephroblastoma, run by Universitätsklinikum Hamburg-Eppendorf at 2 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Life of the parents (EQ-5D) (time frame: 1 minutes). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2024.